Odyssey Therapeutics Reports Positive Phase IIa Results for Ulcerative Colitis Drug

Odyssey Therapeutics presented results from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative colitis, during its UEG Week 2026 investor webcast. The company reported that the 20 mg twice-daily dose met the primary endpoint, showing a mean 2.4-point reduction in modified Mayo score across the study. At this dose, Odyssey reported 27% clinical remission, nearly 50% symptomatic remission, and over 60% clinical response at week 12.

The positive clinical and biomarker results for OD-001 reinforce the company's selection of the 20 mg twice-daily dose for further drug development. This success in the trial could increase the company's valuation and Glick's professional standing.